C-terminal cross-linking telopeptide as a serologic marker for bisphosphonate-related osteonecrosis of the jaw: review of 2 cases.

Abstract

With the increasing use of the bisphosphonate class of drugs, dental professionals are encountering more cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ). The C-terminal cross-linking telopeptide (CTX) assay is a serologic test to predict the risk of BRONJ. This paper examines the effectiveness of CTX as a biochemical marker for BRONJ and its utility to the dentist in establishing appropriate treatment plans for patients with a history of bisphosphonate use. Alternative means of assessing the risk of BRONJ are discussed, and 2 case vignettes are presented to demonstrate dental treatment planning for patients with a history of bisphosphonate use, in the context of specific CTX results.

• Authors: Michael Pasoff
• Journal: Journal (Canadian Dental Association) (J Can Dent Assoc) Vol. 79 Pg. d51 ( 2013) ISSN: 1488-2159 [Electronic] Canada
• PMID: 23920073 (Publication Type: Case Reports, Evaluation Study, Journal Article, Review)

Chemical References

• Biomarkers
• Bone Density Conservation Agents
• Collagen Type I
• Diphosphonates
• Peptides
• collagen type I trimeric cross-linked peptide

Topics

• Adolescent
• Adult
• Aged, 80 and over
• Biomarkers
• Bisphosphonate-Associated Osteonecrosis of the Jaw (blood, diagnosis)
• Bone Density Conservation Agents (adverse effects)
• Child
• Child, Preschool
• Collagen Type I (blood)
• Contraindications
• Dental Implantation, Endosseous
• Dental Prosthesis, Implant-Supported
• Diagnosis, Differential
• Diphosphonates (adverse effects)
• Female
• Humans
• Male
• Middle Aged
• Multiple Myeloma (drug therapy)
• Peptides (blood)
• Predictive Value of Tests
• Standard of Care
• Tooth Extraction
• Young Adult